Phase 3 Trial Results for Stempeutics Cell Therapy in Knee Osteoarthritis Published in American Journal of Sports Medicine (AJSM)
Retrieved on:
Wednesday, August 23, 2023
Communications, Health, Clinical Trials, Publishing, Pharmaceutical, Biotechnology, Osteoarthritis, Medicine, American Journal of Sports Medicine, Disease, Sports medicine, Stiffness, Quality of life, VAS, Cartilage, AJSM, TSP-2, Kellgren, Microsoft Exchange Server, MS, Degenerative disease, MRI, Kasturba Medical College, American Journal, Patient, WOMAC, Regulatory affairs, Rush University Medical Center, American Orthopaedic Society for Sports Medicine, Conference, Inflammation, Pharmaceutical industry, Medical imaging, Knee
Stempeutics, a leader in allogeneic cellular medicines for inflammatory diseases, announced the publication of the Knee OA Phase 3 trial results in the premier journal, the American Journal of Sports Medicine (AJSM).
Key Points:
- Stempeutics, a leader in allogeneic cellular medicines for inflammatory diseases, announced the publication of the Knee OA Phase 3 trial results in the premier journal, the American Journal of Sports Medicine (AJSM).
- Stempeutics has analysed the potency of Stempeucel-OA by their ability to secrete pro-chondrogenic factors such as TSP-2.
- Dr Pawan Gupta, President, Medical & Regulatory Affairs, Stempeutics, said, "The Stempeucel-OA product is developed from Stempeucel® Technology, i.e.
- We have administered Stempeucel-OA using ultrasound guidance and used T2 mapping MRI techniques to assess the quality of articular cartilage.